Lixte Biotechnology Holdings Stock Performance
| LIXTW Stock | USD 0.03 0 21.30% |
On a scale of 0 to 100, Lixte Biotechnology holds a performance score of 3. The company secures a Beta (Market Risk) of 4.74, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lixte Biotechnology will likely underperform. Please check Lixte Biotechnology's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to make a quick decision on whether Lixte Biotechnology's current price movements will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotechnology Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Lixte Biotechnology showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | LIXT stock touches 52-week low at 1.53 amid market challenges - Investing.com | 10/28/2024 |
| Begin Period Cash Flow | 5.4 M |
Lixte |
Lixte Biotechnology Relative Risk vs. Return Landscape
If you would invest 4.20 in Lixte Biotechnology Holdings on August 28, 2024 and sell it today you would lose (1.41) from holding Lixte Biotechnology Holdings or give up 33.57% of portfolio value over 90 days. Lixte Biotechnology Holdings is currently producing 0.7979% returns and takes up 17.3535% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Lixte, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Lixte Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lixte Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lixte Biotechnology Holdings, and traders can use it to determine the average amount a Lixte Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.046
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LIXTW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 17.35 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.8 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Lixte Biotechnology is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lixte Biotechnology by adding it to a well-diversified portfolio.
Lixte Biotechnology Fundamentals Growth
Lixte Stock prices reflect investors' perceptions of the future prospects and financial health of Lixte Biotechnology, and Lixte Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lixte Stock performance.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 1.08 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 313.86 K | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Market Capitalization | 39.49 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
About Lixte Biotechnology Performance
Evaluating Lixte Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lixte Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lixte Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.18) | (1.24) | |
| Return On Capital Employed | (1.27) | (1.34) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | (1.27) | (1.34) |
Things to note about Lixte Biotechnology performance evaluation
Checking the ongoing alerts about Lixte Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lixte Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lixte Biotechnology is way too risky over 90 days horizon | |
| Lixte Biotechnology has some characteristics of a very speculative penny stock | |
| Lixte Biotechnology appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (5.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lixte Biotechnology Holdings has accumulated about 1.08 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lixte Biotechnology has a poor financial position based on the latest SEC disclosures |
- Analyzing Lixte Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lixte Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Lixte Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lixte Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lixte Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lixte Biotechnology's stock. These opinions can provide insight into Lixte Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.